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transplantation (allo-SCT) were compared regarding the use of reduced-intensity conditioning (RIC) and high-intensity
conditioning (HIC) regimens as well as human leukocyte antigen (HLA)-matched and HLA-mismatched grafts.
Patients and methods: We retrospectively analyzed data of 87 ET patients from the European Group for Blood and
Marrow Transplantation, Pediatric Registry for Stem Cell Transplantations, Asia Pacific Blood and Marrow
Transplantation and MetaEICESS registries treated with allo-SCT. Fifty patients received RIC (group A) and 37 patients
received HIC (group B). Twenty-four patients received HLA-mismatched grafts and 63 received HLA-matched grafts.
Results: Median overall survival was 7.9 months [61.24, 95% confidence interval (CI) 5.44–10.31] for group A and
4.4 months (61.06, 95% CI 2.29–6.43) for group B patients (P = 1.3). Death of complications (DOC) occurred in 4 of
50 (0.08) and death of disease (DOD) in 33 of 50 (0.66) group A and in 16 of 37 (0.43) and 17 of 37 (0.46) group B
patients, respectively. DOC incidence was decreased (P < 0.01) and DOD/relapse increased (P < 0.01) in group A
compared with group B. HLA mismatch was not generally associated with graft-versus-Ewing tumor effect (GvETE).
Conclusions: There was no improvement of survival with RIC compared with HIC due to increased DOD/relapse
incidence after RIC despite less DOC incidence. This implicates general absence of a clinically relevant GvETE with
current protocols.
Key words: advanced-stage Ewing tumor, allogeneic stem cell transplantation, graft versus tumor effect,
haploidentical stem cell transplantation, reduced/high-intensity conditioning chemotherapy
introduction
Ewing tumors (ET) constitute a cancer entity of highly
malignant, small, round blue cell tumors with features of
neuroectodermal or endothelial differentiation [1–5]. They are
defined by the expression of a chimeric transcript, commonly
deriving from the reciprocal translocation t(11;22)(q24;q12)
that results in formation of an EWS/ETS fusion gene, whose
detection permits a specific molecular genetic diagnosis [6, 7].
The incidence is 3.3 per million in the Western hemisphere with
a peak incidence at the age of 15 years [8]. The most frequent
localization of disease onset is bone tissue, preferentially long
bones and pelvis. Rarely, soft tissue may harbor the primary
tumor site [2]. Metastatic potential is high; approximately 75%
of patients present with local disease at the time of diagnosis,
whereas the remaining 25% initially present with metastatic
disease. Radical surgery alone results in metastatic relapse in the
majority of cases, suggesting occult metastases at diagnosis even
in apparently localized disease. Despite the impressive
improvement of treatment in the last decades using multimodal
approaches, 5-year overall survival (OS) of ET patients with
localized disease remains at 70%, dropping down to <15% in
patients with multifocal primary disease or with early relapse in
most studies. Use of involved compartment irradiation and
systemic high-dose therapy, both with stem cell rescue, may
increase long-term cure rates. However, additional
improvements of survival are warranted [9–14].
The existence of a clinically relevant graft-versus-tumor effect
in patients with ET after allogeneic stem cell transplantation
(allo-SCT) has been a matter of debate [15–17]. Evidence for
a graft-versus-Ewing tumor effect (GvETE) could solely be
deduced from case reports [18–21]. Allo-SCT following high-
intensity conditioning (HIC) or even reduced-intensity
conditioning (RIC) regimens has thus remained a merely
experimental therapy option in advanced-stage Ewing tumor
(AET) patients and a consensus about eligibility criteria is
lacking. In order to clarify this issue, we carried out
a retrospective European Group for Blood and Marrow
Transplantation (EBMT), Pediatric Registry for Stem Cell
Transplantations (PRST), Asia Pacific Blood and Marrow
Transplantation (APBMT) and MetaEICESS registries based
analysis of 87 ET patients who had either received RIC or HIC
before either human leukocyte antigen (HLA)-mismatched or
HLA-matched allo-SCT.
patients and methods
study design and data provenience
We collected and evaluated data of 87 patients who were diagnosed with
ET from 1984 to 2010 from the EBMT (n = 69), APBMT (n = 5), PRST
(n = 18) and MetaEICESS (n = 4) registries. Some patients were listed in
more than one registry. Inclusion criterion was diagnosis of Ewing
sarcoma family of tumors. Diagnosis was based on histopathological
examination and in recently diagnosed patients confirmed by
molecular genetic detection of ET-specific translocations. In the following
sections, patient numbers are followed by specification of respective
proportions given in brackets when appropriate, except when data were
unavailable.
definitions
Engraftment was defined as an absolute neutrophil count ‡0.5 · 109/l after
allo-SCT. In case, patients died within £100 days after allo-SCT or when
information was unavailable, chronic graft versus host disease (cGvHD)
was considered as not assessable. Death of complications (DOC)
constituted any kind of treatment-related death occurring after allo-SCT in
the absence of disease evidence, including engraftment failure. In contrast,
the definition of death of disease (DOD) comprised any death directly
related to either disease progression or relapse. Progressive disease (PD) was
defined as ‡50% progression of tumor volume; stable disease (SD) included
<50% progression, partial remission (PR) as ‡50% reduction and complete
remission (CR) as absence of detectable disease. Residual disease (RD)
included both PD and PR. Relapse-free survival (RFS) was defined as the
time period from the last allo-SCT until the occurrence of any local or
metastatic ET evidence in patients who had reached CR after treatment.
Early relapse was defined as relapse occurrence £24 months after diagnosis
as opposed to the definition of late relapse (‡24 months after diagnosis).
Multifocal disease was defined as three or more involved bone sites and/or
bone marrow (BM) involvement at diagnosis. Secondary malignancy was
defined as any occurrence of post-allo-SCT malignancies other than ET.
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HLA mismatch was defined as one or more allele mismatch in HLA class 1
and/or HLA class 2.
patients
The study population consisted of 49 (0.56) male and 38 (0.44) female
patients. Median age at allo-SCT was 17 years (range 3–49 years).
Depending on the used conditioning regimen before allo-SCT, all patients
were assigned either to group A (RIC) or to group B (HIC). Group A
comprised 50 of 87 (0.57) and group B 37 of 87 (0.43) patients. In total, 63
of 87 (0.72) patients received grafts from either HLA-matched related or
HLA-matched unrelated donors, whereas 24 of 87 (0.28) patients received
either haploidentical or otherwise HLA-mismatched grafts. Eligibility for
allo-SCT was decided upon the following criteria: local and/or metastatic
relapse (n = 27), multifocal primary with/without RD (n = 46) and
autograft mobilization failure (n = 1). After induction and conditioning
treatment, 42 of 87 (0.48) patients were transplanted in CR, 29 (0.33) in PR
and 14 (0.16) in PD. Graft source was only BM in 33 (0.38) patients, only
peripheral blood (PB) in 48 (0.55), BM and PB in 2 (0.02) patients and only
cord blood in 1 (0.01) patient. Thirty-four (0.39) patients had received
autologous grafts, 1 (0.01) patient had received allogeneic graft and 45
(0.52) patients had not received any other graft before allo-SCT. In group
A, 4 (0.08) patients were transplanted before the year 2000 and 46 (0.92) in
2000 or later, whereas in group B, 29 (0.78) patients were transplanted
<2000 and 8 (0.22) ‡2000. The database contained some previously
published patient data [18, 20]. Age and stage distribution did not differ
significantly between both groups. Precise patient data of both groups are
given in Table 1. All patients or their guardians signed informed consent
before therapy. Treatment application relied upon institutional review
board approvals according to the precepts established by the Helsinki
Conference Declaration.
conditioning regimens and graft versus host disease
prophylaxis
RIC regimens were mainly based on the use of fludarabine (60–210 mg/m2;
n = 47), alone or in combination with either/or the following drugs:
melphalan (MEL; 70–150 mg/m2; n = 15), busulfan (BU; 3–12 mg/kg;
n = 13), thiotepa (TT; 5–10 mg/kg; n = 26), cyclophosphamide (CYC;
30–120 mg/kg; n = 14), treosulfan (TREO; 36 or 42 mg/m2; n = 2),
topotecan (6 mg/m2; n = 3), carmustine (320 mg/m2; n = 1) or etoposide
(ETO; dosage unavailable; n = 1) or other nonspecified drugs in
nonmyeloablative doses (n = 1) with or without the application of 2–4 Gy
total body irradiation (TBI; n = 5). Furthermore, in some RIC patients,
treatment comprised the application of antithymocyte globuline (ATG; n =
13), muromonab-CD3 (OKT3; n = 8) and/or alemtuzumab (n = 1). HIC
regimens were mainly based on the use of TBI (10–14 Gy; n = 23) in
combination with either/or the following drugs: MEL (120–210 mg/m2; n =
25), BU (8–16 mg/kg; n = 9), ETO (800–2100 mg/m2; n = 18), carboplatin
(800–1500 mg/m2; n = 9), CYC (45–150 mg/kg; n = 7), TT (600 or 3300
mg/m2; n = 3), TREO (42 mg/m2; n = 2), vincristine (2 or 2.5 mg/m2; n = 2)
or other nonspecified drugs in myeloablative doses (n = 1). At least one
group B patient received additional ATG. For assessment of conditioning
regimens, only the effect of the latest allo-SCT was analyzed even when
some patients had received auto- or allografts before. Graft versus host
disease (GvHD) prophylaxis included methotrexate, mycophenolat-mofetil,
cyclosporine A and/or prednisolone. Individual regimens are provided in
the supplemental Tables S1 and S2 (available at Annals of Oncology online).
statistical analysis
End points were assessed upon the date of last patient contact. Final
database update was conducted in June 2010. Statistical analyses were
carried out using R 2.11.0 (The R Foundation for Statistical Computing,
Vienna, Austria) and the PASW Statistics v18.0 (SPSS Inc, Chicago, IL)
software. Time values for DOC and relapse/DOD estimates were assessed
starting on the date of the last allo-SCT until last follow-up (FU) and for
OS, until FU and/or until the occurring event was death independent of the
cause. In multivariate analyses, considered variables were patient age, sex,
disease status and conditioning regimen for allo-SCT. Hazard ratios,
standard errors and confidence intervals (CI) are given when appropriate.
For calculation of OS probabilities, the Kaplan–Meier estimate was used.
OS curves were compared using the two-tailed log-rank test. Associations of
patient characteristics and conditioning regimens with OS were evaluated
in multivariate analyses using Cox proportional hazards.
Cumulative incidence curves were applied to estimate the occurrence of
relapse/DOD and DOC, with DOC being a competing event for relapse/
DOD and vice versa. For comparison of relapse/DOD incidence between
HLA-matched and HLA-mismatched patients, DOC was the competing
event. When DOD/relapse and DOC were competing events, uni- and
multivariate risk analyses were conducted using the cmprsk and the
crr-addson packages designed for R, as proposed by Scrucca et al. [22, 23].
In uni- and multivariate analyses, probabilities of relapse/DOD or DOC
for potential explanatory variables were compared using Gray’s test or




Seventy-nine (0.91) patients engrafted successfully, whereas 7
(0.08) patients failed to engraft and for 1 patient, engraftment
data were not available. Overall, acute graft versus host disease
(aGvHD) was reported in 39 (0.45) patients and absent in 44
(0.51). Overall, cGvHD occurred in 12 (0.14) patients, was
absent in 31 (0.36) patients and was not assessable due to either
death/last FU before day 100 after allo-SCT in 37 (0.42)
patients or to otherwise unavailable information in 7 (0.08)
patients. Within group A, 15 (0.30) patients presented with
limited and 10 (0.20) with extensive aGvHD, whereas 24 (0.48)
patients did not develop aGvHD. Four (0.08) group A patients
developed limited, 3 (0.06) developed extensive and 17 (0.34)
did not have cGvHD. Status information remained unavailable
in 26 (0.52) group A patients due to early death or last FU
before day 100 after allo-SCT. Within group B, eight (0.22)
patients developed limited and six (0.16) developed extensive
aGvHD. In 20 (0.54) group B patients, aGvHD was not
detectable. Limited cGvHD was present in three (0.08) and
extensive cGvHD in two (0.05) further patients. Status
information remained unavailable in 18 (0.49) group B patients
due to early death or last FU before day 100 after allo-SCT. An
overview is given in Table 2.
overall survival
The 5-year OS estimate for groups A and B was 0.15 (60.07)
and 0.10 (60.05), respectively. OS time did not differ
significantly between both groups (Figure 1; log rank P =
0.133). At the time of data censure, 37 of 50 (0.74) group A and
33 of 37 (0.89) group B patients had died due to disease or due
to complications. Thirteen (0.26) group A and four (0.11)
group B patients were alive in CR except for one group A
patient who had SD. Median OS was 7.9 months (61.24; 95%
CI 5.44–10.31) for group A and 4.4 months (61.06; 95% CI
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Table 1. Patient characteristics
Parameter Group A (RIC, n = 50) Group B (HIC, n = 37)





£15 years 30 0.60 21 0.57





£15 years 19 0.38 20 0.54





<2000 11 0.22 28 0.76
‡2000 39 0.78 9 0.24
Period of allo-SCT
<2000 4 0.08 25 0.68
‡2000 46 0.92 12 0.32
Risk profile leading to allo-SCT
Early relapsea 7 0.14 5 0.14








0 0.00 1 0.03
Not available 3 0.06 10 0.27
Primary site





8 0.16 2 0.05
Multifocal 21 0.42 17 0.46
Local soft tissue
only
1 0.02 0 0.00
Not available 5 0.10 10 0.27
Local treatment modality
Surgery only 12 0.24 5 0.14
Irradiation only 11 0.22 8 0.22
Surgery +
irradiation
19 0.38 15 0.41
None 3 0.06 0 0.00
Not available 5 0.10 9 0.24
Previous graft
No previous graft 14 0.28 31 0.84
Allogeneic graft
once
1 0.02 0 0.00
Autologous graft
once
24 0.48 1 0.03
Autologous graft
twice or more
7 0.14 2 0.05
Not available 4 0.08 3 0.08
Table 2. Results
Parameter Group A (RIC, n = 50) Group B (HIC, n = 37)
Number Fraction Number Fraction
Engraftment
Success 47 0.94 32 0.86
Failure 3 0.06 4 0.11
Not available 0 0.00 1 0.03
aGvHD
None 24 0.48 20 0.54
Limited 15 0.30 8 0.22
Extensive 10 0.20 6 0.16
Not available 1 0.02 3 0.08
cGvHD
None 17 0.34 14 0.38
Limited 4 0.08 3 0.08
Extensive 3 0.06 2 0.05
NA due to death
or last FU £
day 100
22 0.44 15 0.41
Not available 4 0.08 3 0.08
Outcome
DOC 4 0.08 16 0.43
DOD 33 0.66 17 0.46
Alive at last FU 13 0.26 4 0.11
Median OS (months after allo-SCT)
Median 7.9 4.4
Range 0–67 0–213
RIC, reduced-intensity conditioning; HIC, high-intensity conditioning;
aGvHD, acute graft versus host disease; cGvHD, chronic graft versus host
disease, FU, follow-up; DOC, death of complications; DOD, death of
disease; OS, overall survival; allo-SCT, allogeneic stem cell transplantation.
Table 1. (Continued)
Parameter Group A (RIC, n = 50) Group B (HIC, n = 37)
Number Fraction Number Fraction
Donor HLA match
Matched related 27 0.54 32 0.86
Matched unrelated 3 0.06 1 0.03
Mismatchedb 20 0.40 4 0.11
Graft source
BM only 8 0.16 25 0.68
PB only 39 0.78 9 0.24
BM + PB 2 0.04 0 0.00
CB only 1 0.02 0 0.00
Not available 0 0.00 3 0.08
Pretransplant status
CR 22 0.44 20 0.54
PR 17 0.34 12 0.32
PD 10 0.20 4 0.11
Not available 1 0.02 1 0.03
aIncluding multifocal relapse in some patients.
bOne or more allele mismatch in HLA class 1 and/or HLA class 2.
RIC, reduced-intensity conditioning; HIC, high-intensity conditioning;
allo-SCT, allogeneic stem cell transplantation; HLA, human leukocyte
antigen; BM, bone marrow; PB, peripheral blood; CB, cord blood; CR,
complete remission; PR, partial remission; PD, progressive disease.
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2.29–6.43) for group B patients, respectively. An overview is
provided in Table 2.
relapse and DOD
The 5-year estimate for relapse/DOD was 0.81 (60.08) for
group A patients and 0.47 (60.09) for group B patients.
Overall, 33 of 50 (0.66) group A patients and 17of 37 (0.46)
group B patients had a relapse and/or died of their disease
(Table 2). Overall, risk of relapse/DOD was significantly higher
within group A as compared with group B (Figure 2A, Gray’s
test P = 0.009).
death of complications
The 5-year and overall DOC estimate was 0.08 (60.04) for
group A and 0.43 (60.08) for group B patients. Main reasons
causing DOC were occurrences of infection, hemorrhage, veno-
occlusive disease and GvHD. Overall, risk of DOC was
significantly lower within group A as compared with group B
(Figure 2B, Gray’s test P = 0.0002).
HLA-mismatched versus HLA-matched grafts
In this setting, time periods from the date of the last allo-SCT
until the occurrence of relapse/DOD were compared between
those patients who had received HLA-mismatched with those
who had received HLA-matched grafts. DOC was considered as
a competing event for relapse/DOD. Twenty-four of 87 (0.28)
patients had received HLA-mismatched and 63 of 87 (0.72)
patients had received HLA-matched grafts. The 3-year estimate
for relapse/DOD was 0.62 (60.13) for patients with HLA-
mismatched grafts and 0.64 (60.06) for patients with HLA-
matched grafts. The 3-year estimate for DOC was 0.22 (60.09)
for patients with HLA-mismatched grafts and 0.24 (60.05) for
patients with HLA-matched grafts. Neither group had an OS or
RFS advantage (Figure 3A, Gray’s test P = 0.89; Figure 3B,
Gray’s test P = 0.95).
multivariate analysis
Upon multivariate analyses, none of the considered variables
age, sex, conditioning regimen and disease stage at allo-SCT
had an influence on OS outcome. Age just marginally failed to
reach statistical significance as an influential factor for OS
(Wald test P = 0.05). Employment of RIC was associated with
an increased relapse/DOD versus DOC rate (Wald test P =
0.021) compared with HIC regimens (Table 3).
Figure 2. Probabilities and group comparisons of time periods from the
date of allogeneic stem cell transplantation (allo-SCT) until (A) relapse/
death of disease (DOD) and (B) death of complications (DOC) between
patients treated with reduced-intensity conditioning (RIC; group A, n =
50) versus high-intensity conditioning (HIC; group B, n = 37) regimen in
a competitive risk setting between DOD and DOC. Patients alive at last
follow-up were censored. P values < 0.05 (Gray’s test) indicate significant
difference.
Figure 1. Overall survival probabilities from the date of allogeneic stem
cell transplantation (allo-SCT) for patients treated with reduced-intensity
conditioning (RIC; group A, n = 50) versus high-intensity conditioning
(HIC; group B, n = 37) regimen; patients alive at last follow-up were
censored. The differences are not significant (log rank, P > 0.5).
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discussion
Allo-SCT has been applied as a therapeutic option for patients
with AET [18]. Koscielniak et al. as well as Lucas et al. reported
on AET patients who had experienced tumor regression
following allo-SCT [20, 21]. However, the GvETE may be
associated with toxicity of GvHD. In addition to natural killer
cell-mediated toxicity, the broad T-cell allo-response poses
a significant problem in clinical transplantation across HLA
incompatibilities [24].
The use of myeloablative conditioning before allo-SCT has
led to improved disease response but implicated pronounced
treatment-related toxicity [14, 25–27], which in turn has led to
a shift toward the implementation of less toxic RIC regimens in
the last decade. This shift was expected to diminish incidence of
DOC and thus to enhance the conditions for a GvETE to
engage. We retrospectively compared clinical outcome of allo-
SCT in ET patients who had either received RIC (group A) or
HIC (group B) before allo-SCT in regard to age at
transplantation, toxicity, RFS and OS. Median age, disease stage
and indications for allo-SCT were comparable. Both groups
contained HLA-related and nonrelated matched and
mismatched donor/recipient combinations, including
haploidentical transplants. We hypothesized a clinically
relevant GvETE in ET patients treated with allo-SCT and
assessed its possible presence by comparing the relapse/DOD
rates between both groups. In group A (RIC), DOC rate (0.08)
was reduced and DOD rate (0.66) was increased compared with
group B (HIC, DOC 0.43 and DOD 0.46). Compared with the
application of HIC, RIC-mediated protection from DOC was
significantly higher in uni- and multivariate analyses (P < 0.05).
However, the lower DOC rate in the RIC-treated patients did
not translate into improved survival but was associated with
a higher relapse/DOD rate in group A as compared with group
B and did not improve OS. Sex, disease status and age at allo-
SCT were neither associated with improved time until relapse/
DOD nor with OS in either setting.
Despite higher incidence of relapse/DOD due to lower
incidence of DOC in patients treated with RIC, comparison of
RFS and OS between both groups demonstrated that neither
Figure 3. Comparison of survival rates in a competitive risk setting
between relapse/death of disease (DOD) and death of complications
(DOC) from the date of allogeneic stem cell transplantation (allo-SCT)
until relapse/DOD (A) or until DOC (B) of patients receiving human
leukocyte antigen (HLA)-mismatched or HLA-matched grafts. Patients
alive at last follow-up were censored. Neither graft type provides
a significant survival advantage (Gray’s test, P > 0.5).
Table 3. Multivariate analysis
HR SE 95% CI P valuea
OS
Recipient age 1.03 0.01 1.00–1.05 0.050
Sex 0.640
Male Referent
Female 0.88 0.27 0.52–1.50
Conditioning 0.068
HIC Referent





CR 0.67 0.25 0.41–1.10
Relapse/DOD
Recipient age 0.99 0.02 0.95–1.03 0.500
Sex 0.580
Male Referent
Female 0.85 0.30 0.48–1.51
Conditioning 0.021
HIC Referent





CR 0.71 0.30 0.40–1.27
aWald test.
HR, hazard ratio; SE, standard error; CI, confidence interval; OS, overall
survival; RIC, reduced-intensity conditioning; HIC, high-intensity
conditioning; RD, residual disease; CR, complete remission; allo-SCT,
allogeneic stem cell transplantation; DOD, death of disease.
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type of conditioning was associated with significantly better
survival rates. This finding indirectly implicates the lack of
a clinically relevant GvETE in current settings. A DOC rate of
0.43 in patients receiving HIC confirms the results of our study
conducted 10 years ago, which revealed a DOC rate of 0.40 in
AET patients treated with matched allogeneic sibling grafts after
HIC [18].
Some patients survived long term after allo-SCT and within
this group some had received haploidentical grafts. We
expected that the application of mismatched grafts would lead
to protection via GvETE and therefore compared relapse/DOD
and DOC outcomes of patients receiving HLA-matched versus
HLA-mismatched grafts, but we could not detect any difference
regarding RFS or OS. In anticipation of a supposed GvETE, the
application of haploidentical transplantations in AET patients
constitutes an approach that has been increasingly
implemented notably during the last decade. In our study,
among those patients who were alive at the time point of data
censure, some had received haploidentical grafts just recently
and were alive, so the long-term effect of this particular allo-
SCT setting cannot yet be determined. Additionally, we did not
address the role of donor lymphocyte infusions (DLI).
Therefore, the question whether allo-SCT in haploidentical
graft settings may yield a clinically relevant GvETE with or
without the use of DLI will remain subject to ongoing
prospective studies. As GvETE may depend on ET-specific as
well as non-ET-specific antigen presentation, it will also be
important to identify further biological eligibility criteria for
haploidentical allo-SCT, i.e. certain HLA mismatch
constellations when choosing the donor.
For data interpretation, it also has to be considered that
group A (RIC) patients were mainly treated during the last 10
years in contrast to group B (HIC) patients who were mostly
treated before this period. This might have an impact on DOC
comparability between both groups, e.g. due to improvement
in supportive therapy, especially for GvHD prophylaxis and
treatment. Furthermore, initial and relapse systemic and local
treatment differed between patients depending on center and
time period and many group A patients had received prior
grafts before allo-SCT. On the other hand, decreased relapse
rates after HIC versus RIC provide further evidence for
antitumor efficacy of high-dose therapy in ET.
Our results emphasize the need for additional therapeutic
strategies for AET that yield antitumor effectiveness with
minimal toxic side-effects. The identification of ET-specific
target antigens [1] may give way to a personalized immune
therapy using ET antigen-specific allo-restricted T cells in
addition to the application of allo-SCT, rendering future
application of DLI more specific and thus more efficacious and
less toxic as seen in the treatment of other cancer entities [24,
28].
In our present study, we aimed to match patient groups as
closely as possible, however, as the effect of allo-SCT demands
large ET patient numbers, the effect of heterogeneity, i.e.
regarding initial diagnostic and local/systemic therapeutic
approaches [29–31] within our study population could not
entirely be taken into account for assessment of comparability.
This is why the conclusions drawn from the present data should
be handled carefully. However, despite the limitations
associated with all retrospective studies, this is, to the best of
our knowledge, the first study to provide a systematic
assessment of outcomes of a large number of ET patients
receiving allo-SCT in different therapeutic settings within
Europe and beyond. A prospective international approach is
warranted to further clarify the issue of allo-SCT in AET.
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